Viewing Study NCT07065435


Ignite Creation Date: 2025-12-24 @ 10:16 PM
Ignite Modification Date: 2025-12-31 @ 11:24 PM
Study NCT ID: NCT07065435
Status: RECRUITING
Last Update Posted: 2025-07-15
First Post: 2025-07-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module